EB101 / Exom BioPharma - LARVOL DELTA

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting (clinicaltrials.gov) - P=N/A | N=250 | Recruiting | Sponsor: Abeona Therapeutics, Inc

New trial

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients (clinicaltrials.gov) - P3 | N=12 | Active, not recruiting | Sponsor: Abeona Therapeutics, Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Sep 2025

Enrollment closed • Trial completion date • Trial primary completion date